- N.Y. prosecutors: Russian diplomats bilked $1.5 million from Medicaid
- Happy Meal: Couple goes to McDonald’s, leaves with bag packed with cash
- Boehner: It took me 3 to 4 hours to sign up for Obamacare
- Oh my God! Costco lists Bible as fiction, Ron Burgundy memoir as gospel
- Sarah Palin responds to Martin Bashir’s resignation, praises media
- Obama to send 2 Gitmo terror suspects back to Algeria
- Paul Walker secretly bought $9K wedding ring for Iraq vet
- Mystery sign poster hits Washington state town: ‘It’s OK to say Merry Christmas’
- Pope Francis forms commission to advise on sex abuse
- Anthony Weiner on radio? Cumulus says, ‘Never, ever’
Antibiotic-resistant ‘superbugs’ alarm health care industry
Health officials are warning of the rise of the “superbugs” — bacteria and other pathogens that cannot be killed by modern medicine.
But many pharmaceutical companies are resisting the call to develop effective antibiotics and instead are shifting their resources to other products.
Exhibit A is AstraZeneca, one of the major companies still working on developing antibiotics.
Its new chief executive, Pascal Soriot, said Monday the drug giant was restructuring its workforce and will focus on three therapy areas: cancer, cardiovascular and metabolism disorders, and respiratory and inflammatory diseases. This means “reduced spending on anti-infectives,” according to Reuters.
Pfizer, Roche, Bristol-Myers Squibb and Eli Lilly have all reduced or eliminated their antibiotic research efforts, while Merck & Co. and GlaxoSmithKline are still actively pursuing such medicines, Reuters added.
The reason businesses resist making new antibiotics is rational: The drugs are expensive to develop but are used briefly by most patients and are aimed at pathogens that eventually learn how to build up a resistance to them.
As a result, there have always been relatively few antibiotic products in development, and now — gauging by what is in the pipeline — “none of them really is going to be active against these bacteria in the near term,” said Dr. Gary A. Roselle, national director of the Infectious Diseases Service for the Department of Veterans Affairs health care system.
“Incentivization” for drug development that may not have major monetary success is a big topic of discussion, added Dr. Roselle, who works at the Veterans Affairs Medical Center in Cincinnati. But in the meantime, “The current goal has to be prevention, wherever possible,” he said.
Public warnings have been issued about multidrug-resistant tuberculosis and gonorrhea, and a hospital-associated infection known as methicillin-resistant Staphylococcus aureus.
A new bug, described as a “nightmare bacteria,” was highlighted in early March by Dr. Thomas Frieden, director of the Centers for Disease Control and Prevention.
Carbapenem-resistant Enterobacteriaceae (CRE) refers to a family of mostly harmless bacteria that live in the gut, and includes E. coli, shigella, salmonella and klebsiella. These bacteria can cause illnesses, including pneumonia, diarrhea and urinary tract infections, if they are swallowed or enter the bloodstream through an open wound.
Carbapenem-resistant refers to some bacteria that become immune to even the “last-resort” class of drugs.
CRE “pose a triple threat” because few, if any, antibiotics can kill them; they are associated with a high mortality rate; and “they can spread their resistance to other bacteria,” Dr. Frieden said.
That last point is of great concern, Dr. Frieden said, because if CRE pathogens transfer their drug-resistance genes to another bacteria such as E. coli, it could make a common illness, such as a urinary tract infection, extremely difficult to treat.
Reports of the rise of the rare but potentially deadly CRE superbugs caught the attention of lawmakers on Capitol Hill.
© Copyright 2013 The Washington Times, LLC. Click here for reprint permission.
About the Author
Cheryl Wetzstein covers family and social issues as a national reporter for The Washington Times. She has been a reporter for three decades, working in New York City and Washington, D.C. Since joining The Washington Times in 1985, she has been a features writer, environmental and consumer affairs reporter, and assistant business editor. Beginning in 1994, Mrs. Wetzstein worked exclusively ...
- Embryonic stem cell research falls out of favor as scientists go ethical
- With new HIV research, FDA may let gay men donate blood
- HHS report shows a decrease in blood supply but also a drop in demand
- Little change in practice for China's one-child family policy
- Gay-marriage momentum comes to a sudden halt after Illinois
Latest Blog Entries
- Pro-life, stem-cell bill signed into law by Kansas Gov. Sam Brownback
- N. Dakota lawmakers approve tough abortion bill
- Pope Benedict XVI's successor should allow priests to get a new title: Husband, poll finds
- House votes to reject Obama welfare shift
- Report: Two out of three Democrats support gay marriage
- CURL: 'Mission Accomplished' for Obamacare
- Hack attack: 2 million Facebook, Twitter passwords stolen
- Obama returns to class warfare as poll numbers plunge
- 'Hunger Games' delivers Obama's message on income inequality: liberal group
- NAPOLITANO: Pope Francis should be saving souls, not pocketbooks
- Democratic infighting erupts over 'we can have it all' fantasy on entitlements
- Inside China: Nuclear submarines capable of widespread attack on U.S.
- American teacher shot and killed at Benghazi international school
- U.S. drops 2,000 mice on Guam by parachute to kill snakes
- At minimum, a bad deal
Independent voices from the The Washington Times Communities
Entertainment News and Reviews from Washington, D.C. and beyond.
We’re not all having tea with the Queen you know.
Happiness is attainable. Morning to night. I love to teach, deal with folks that have an issue and really wish to tackle it and write.
Film Reviews and Articles by Kevin Williams
White House pets gone wild!